No sooner does one gammadelta-focused biotech die than another takes its place.
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
The two companies have been involved in recent licensing deals.
The company discontinues the Lag3 project in lung cancer.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
